AnaptysBio, Inc. (ANAB): Price and Financial Metrics

AnaptysBio, Inc. (ANAB): $27.31

0.03 (+0.11%)

POWR Rating

Component Grades













Add ANAB to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where ANAB ranks best; there it ranks ahead of 60.24% of US stocks.
  • The strongest trend for ANAB is in Value, which has been heading down over the past 179 days.
  • ANAB ranks lowest in Sentiment; there it ranks in the 3rd percentile.

ANAB Stock Summary

  • With a price/sales ratio of 173, ANAPTYSBIO INC has a higher such ratio than 98.31% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, ANAPTYSBIO INC is reporting a growth rate of -1,707.64%; that's higher than only 0.77% of US stocks.
  • Revenue growth over the past 12 months for ANAPTYSBIO INC comes in at -96.33%, a number that bests just 0.97% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to ANAPTYSBIO INC, a group of peers worth examining would be CCCC, CARA, MRTX, PRTA, and AEVA.
  • Visit ANAB's SEC page to see the company's official filings. To visit the company's web site, go to

ANAB Valuation Summary

  • ANAB's EV/EBIT ratio is -5.6; this is 165.12% lower than that of the median Healthcare stock.
  • Over the past 71 months, ANAB's EV/EBIT ratio has gone up 64.5.

Below are key valuation metrics over time for ANAB.

Stock Date P/S P/B P/E EV/EBIT
ANAB 2022-11-25 178.3 2.9 -5.9 -5.6
ANAB 2022-11-23 177.0 2.9 -5.9 -5.6
ANAB 2022-11-22 176.9 2.9 -5.9 -5.6
ANAB 2022-11-21 171.2 2.8 -5.7 -5.4
ANAB 2022-11-18 172.7 2.8 -5.8 -5.5
ANAB 2022-11-17 178.4 2.9 -5.9 -5.7

ANAB Growth Metrics

    Its 4 year price growth rate is now at -23.75%.
  • The 3 year net cashflow from operations growth rate now stands at 16.11%.
  • Its 3 year cash and equivalents growth rate is now at 57.12%.
ANAB's revenue has moved up $1,490,000 over the prior 52 months.

The table below shows ANAB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 4.49 -88.209 -134.849
2022-06-30 24.087 -77.468 -108.013
2022-03-31 52.898 -43.73 -75.888
2021-12-31 63.175 -45.92 -57.796
2021-09-30 122.164 16.959 8.388
2021-06-30 101.274 6.952 -8.713

ANAB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ANAB has a Quality Grade of C, ranking ahead of 73.88% of graded US stocks.
  • ANAB's asset turnover comes in at 0.294 -- ranking 156th of 682 Pharmaceutical Products stocks.
  • AUPH, OCX, and LFVN are the stocks whose asset turnover ratios are most correlated with ANAB.

The table below shows ANAB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.294 1 0.079
2021-06-30 0.249 1 -0.071
2021-03-31 0.178 1 -0.215
2020-12-31 0.184 1 -0.115
2020-09-30 0.044 1 -0.376
2020-06-30 0.042 1 -0.370

ANAB Price Target

For more insight on analysts targets of ANAB, see our ANAB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.33 Average Broker Recommendation 1.79 (Moderate Buy)

ANAB Stock Price Chart Interactive Chart >

Price chart for ANAB

ANAB Price/Volume Stats

Current price $27.31 52-week high $37.40
Prev. close $27.28 52-week low $18.20
Day low $26.48 Volume 371,800
Day high $27.96 Avg. volume 254,028
50-day MA $27.69 Dividend yield N/A
200-day MA $24.76 Market Cap 776.48M

AnaptysBio, Inc. (ANAB) Company Bio

AnaptysBio Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. The company was founded in 2005 and is based in San Diego, California.

ANAB Latest News Stream

Event/Time News Detail
Loading, please wait...

ANAB Latest Social Stream

Loading social stream, please wait...

View Full ANAB Social Stream

Latest ANAB News From Around the Web

Below are the latest news stories about ANAPTYSBIO INC that investors may wish to consider to help them evaluate ANAB as an investment opportunity.

AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday November 29th, 2022, at 8:10 a.m. ET / 5:10 a.m. PT. A live audio webcast of the presentation will be available on the investor section

Yahoo | November 21, 2022

AnaptysBio Third Quarter 2022 Earnings: Misses Expectations

AnaptysBio ( NASDAQ:ANAB ) Third Quarter 2022 Results Key Financial Results Net loss: US$33.5m (loss widened by 403...

Yahoo | November 11, 2022

AnaptysBio to Participate in Upcoming November Investor Conferences

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at

Yahoo | November 9, 2022

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update

Anticipate Rosnilimab, our anti-PD-1 agonist antibody, top-line data in the ongoing AZURE Phase 2 trial in moderate-to-severe alopecia areata in Q1 2023Anticipate ANB032, our anti-BTLA agonist antibody, U.S. IND submission for a Phase 2 trial in Q4 2022Announced our third wholly owned immune cell modulator program, ANB033, our anti-CD122 antagonist antibody, with a U.S. IND submission for a Phase 1 trial in 1H 2024Sold our interest in future Zejula royalties to a wholly-owned subsidiary of DRI H

Yahoo | November 8, 2022

Read More 'ANAB' Stories Here

ANAB Price Returns

1-mo -6.54%
3-mo 9.94%
6-mo 30.30%
1-year -13.77%
3-year 90.85%
5-year -67.64%
YTD -21.41%
2021 61.63%
2020 32.31%
2019 -74.53%
2018 -36.67%
2017 N/A

Continue Researching ANAB

Here are a few links from around the web to help you further your research on Anaptysbio Inc's stock as an investment opportunity:

Anaptysbio Inc (ANAB) Stock Price | Nasdaq
Anaptysbio Inc (ANAB) Stock Quote, History and News - Yahoo Finance
Anaptysbio Inc (ANAB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6422 seconds.